24-hour Holter ECG Research Articles

Morphology and clinical significance of mitral valve prolapse among the polish population of the MITPROL AR-PL registry

Abstract Introduction The role of mitral valve prolapse (MVP) as an arrhythmic substrate rather than an isolated structural defect is under investigation. There is a possible link between the MVP, its morphology, and arrhythmic MVP (aMVP). Purpose To obtain data on the morphology and clinical significance of MVP in the Polish population. Methods 417 patients with MVP (mean age 45.5 years-yrs.; females: 249/59.7%) were enrolled into the prospective observational registry MITPROL AR-PL of the Polish Cardiac Society. Data was obtained from 23 Polish tertiary medical centers; the recruitment lasted 12 months. The analysis included demographics, clinical symptoms, 12-lead ECG, 24-hour Holter ECG, transthoracic, and transesophageal echocardiography. The MVP morphology was analyzed and defined as Barlow’s disease (BD), Forme Fruste (FF), and Fibroelastic deficiency (FED), according to standardized criteria. Groups were dichotomized into aMVP and non-arrhythmic MVP (non-aMVP) following the 2022 European Heart Rhythm Association consensus [1]. Patients who fulfilled the arrhythmic criteria but had proarrhythmic comorbidities comprised the MVP A+C (arrhythmia + comorbidities) group. Analysis was performed for the total population and age-divided subgroups: pediatric (0-18 yrs.), young adults (19-45 yrs.), middle-aged (46-59 yrs.), elderly (60+ yrs.). Results MVP population in the age subgroups: pediatric 86 (20%), young adults 120 (29%), 67 (16%) middle-aged, 144 (35%) elderly. BD was present in 140 (34%), FF in 242 (58%), and FED in 35 (8%). Bileaflet prolapse occurred in 228 (55%), anterior leaflet prolapse in 65 (16%), and posterior leaflet prolapse in 124 (29%). The frequency of the MVP morphology in the consecutive age subgroups was akin. The aMVP group consisted of 62 (15%), non-AMVP 336 (80%), and MVP A+C of 19 (5%) patients. Distribution of aMVP in the age subgroups: pediatric- 11%, young adults- 42%, middle-aged- 23%, elderly- 24%, 76% of aMVP patients were < 60 yrs. The aMVP corresponded mainly to the following MVP morphology: BD– 29 (47%) vs. 103(31%) in non-AMVP (p=0.01). Bileaflet prolapse was the most frequent for aMVP (46/74%) vs. non-aMVP (175/52%) (p=0.001), respectively anterior leaflet prolapse 4 (7%) vs. 57 (17%) (p=0.03), posterior leaflet prolapse 12 (19%) vs. 104 (31%) (p=0.06). Moderate to severe MR was observed in 35 (56%) aMVP vs. 196 (58%) non-aMVP (p=0.8), MAD in 48 (77%) aMVP vs. 193 (57%) non-aMVP (p=0.003), Pickelhaube sign in 28 (45%) aMVP vs. 98 (29%) non-AMVP cases (p=0.01). MAD diameter was higher in the aMVP (8.6 ± 2.7 mm) vs. the non-aMVP (7.2 ± 2.5 mm) group (p=0.001). The age of MVP A+C group was higher, with 84% of patients >60 yrs. vs. 24% >60 yrs. in the aMVP (p<0.0001). MVP morphology in the MVP A+C was: BD 8 (42%), FF 10 (53%), and FED 1 (5%). Conclusion The MVP is a primary and heterogenous disease, and aMVP variant is rare. The aMVP population differs significantly from non-AMVP and MVP A+C populations. Mitprol AR-PL Methodology Mitprol AR-PL Population

Arrhythmogenic mitral annular disjunction: papillary muscle abnormalities as a novel component

Abstract Purpose Mitral annular disjunction (MAD) is a relatively common condition that can be associated with ventricular arrhythmias. This study aims to assess the significance of abnormalities in the left ventricular papillary muscles, as detected by cardiac magnetic resonance imaging (MRI), and their correlation with the echocardiographic Pickelhoube sign and arrhythmogenic burden in patients with MAD. Methods and Materials A retrospective study was conducted involving 63 consecutive patients with MAD identified via a 1.5T MRI scanner. All patients underwent echocardiography, and 51 patients (81%) also completed a 24-hour Holter electrocardiography. The study evaluated the visual presence of the dark papillary muscle sign (dark PAP), late gadolinium enhancement in the papillary muscles (PAP LGE), and the echocardiographic Pickelhoube sign, known to be associated with a higher risk of ventricular arrhythmias. Additionally, the 24-hour Holter ECG assessed the number of premature ventricular contractions (PVCs), using a threshold of more than 1000 beats per 24 hours, and the presence of nonsustained ventricular tachycardia (nsVT). Results The average MAD length in the study population was 5.29 ± 0.43 mm (95% CI). The dark PAP sign was observed in 42 patients (67%), PAP LGE in 11 patients (17%), and the echocardiographic Pickelhoube sign in 34 patients (54%). Ventricular arrythmias (nsVT and more than 1000 PVCs per 24 hours) were found in 24 patients (38%). The dark PAP sign was significantly associated with the echocardiographic Pickelhoube sign (p < 0.001). Ventricular arrhythmias (PVCs) were more frequent in patients with PAP LGE (p < 0.03). The small number of nsVT cases (6 patients) precluded statistical analysis. Conclusion The study found that the dark PAP sign correlates with the echocardiographic Pickelhoube sign, and PAP LGE is associated with a higher burden of ventricular arrhythmias. Further prospective studies in larger populations are needed to evaluate the potential of papillary muscle characteristics in risk stratification for ventricular arrhythmias in patients with MAD. dark PAP positive dark PAP negative

Severe bradycardia in patients with obstructive sleep apnoea and good early response to CPAP.

Obstructive sleep apnoea (OSA) may lead to heart rhythm abnormalities including bradycardia. Our aim was to ascertain clinical and echocardiographic parameters in patients with OSA in whom severe bradycardia was detected in an outpatient setting, as well as to evaluate the efficacy of CPAP therapy on heart rate normalization at the early stages of treatment. Fifteen patients mild, moderate or severe OSA and concomitant bradycardia were enrolled. A standard non-invasive diagnostic assessment protocol was followed, including blood tests and echocardiography. The 24-hour Holter ECG was performed to confirm the presence of bradycardia and determine its subtype. Then CPAP therapy was commenced. Throughout the hospitalisation, continued cardiac monitoring was used in all patients, and 3-4 days following CPAP therapy commencement, a follow-up 24-hour Holter ECG was performed. Out of 15 patients observed, 3 patients did not consent to CPAP therapy, and one patient had to undergo emergency pacemaker implantation before he was started on CPAP. A complete resolution of bradycardia and cardiac conduction abnormalities was achieved in the remaining 11 patients by day 4. of treatment. The mean lowest recorded HR was 52.7bpm as compared to 33.9bpm before CPAP therapy commencement (p < 0.0002). Sinus pauses exceeding 2.5s were not detected in any of those patients. OSA may be comorbid with and precipitate severe bradycardia. CPAP therapy enabled rapid resolution of bradycardia in more than 80% of our cohort, which may potentially prevent pacemaker implantation provided they remain compliant.

Influence of platelet hemostasis on QT interval dispersion in patients with chronic ischemic heart disease and COVID-19

Coronavirus disease COVID-19 impairs platelet hemostasis, heart rate variability (HRV) and QT interval dispersion, increasing the risk of thromboembolic complications and cardiovascular mortality. Our study aimed to investigate the impact of COVID-19 on the interdependence of changes in platelet hemostasis and QT interval dispersion in patients with ischemic heart disease (IHD). We analyzed laboratory and instrumental results of 102 patients divided into 3 groups: group 1 consisted of IHD without COVID-19 patients (n = 32); group 2 − IHD in combination with COVID-19 (n = 35); group 3 − COVID-19 without IHD (n = 35). The control group included 30 conditionally healthy volunteers. Changes in platelet hemostasis were studied with laser aggregometry using the Born turbidimetric method and with light transmission fluctuation analysis using an assessment of spontaneous and induced aggregation: adenosine diphosphate (ADP), arachidonic acid, epinephrine, collagen, and ristomycin. The results of 24-hour Holter ECG monitoring were used to determine the QT interval dispersion. In patients of group 2, there was an increase in the degree, rate and time of spontaneous platelet aggregation, as well as a decrease in the degree, rate and time of platelet aggregation induced by epinephrine, a decrease in the rate of aggregation induced by arachidonic acid and ADP. The degree of aggregation was higher when using collagen and ristomycin. The QT interval duration and variability increased in all patients, especially in group 2. The time of spontaneous aggregation, as well as ADP- and collagen-induced aggregation, was directly correlated with the QT mode and mean. The standard deviation and coefficient of variation of QT were inversely related to the time of spontaneous aggregation, collagen- and ristomycin-induced and arachidonic acid-induced aggregation. The rate of aggregation did not affect the QT interval variability. Thus, patients with IHD and concomitant COVID-19 along with platelet hemostasis dysfunction exhibited signs of autonomic dysregulation and increased QT interval duration and variability. Careful consideration of platelet hemostasis characteristics and QT interval variability is recommended in the management of these patients.

Unexplained cardiac arrest (idiopathic ventricular fibrillation): clinical and genetic characteristics

AIM: The study was to evaluate the clinical and genetic characteristics of inherited arrhythmias in patients who survived unexplained cardiac arrest. MATERIALS AND METHODS: 20 patients (10 male and 10 female) aged 15 to 55 years (median age 36 [28; 44] years) with documented VT/VF on ECG were observed for 3 years. The clinical and instrumental study included registration of 12-lead ECG, 24-hour Holter ECG, genealogical history collection and family history of sudden cardiac death with ECG assessment of all family members, transthoracic echocardiography, 2D Speckle Tracking echocardiography and cardiac magnetic resonance imaging to exclude structural myocardial changes. High-throughput sequencing (NGS) was utilized to search for mutations in genes linked to the onset of channelopathies and other inherited rhythm disorders. RESULTS: In 4 (20 %) of the 20 probands included in the study, likely pathogenic variants were identified (pathogenicity class IV), and in 7 (35 %) patients, variants with unknown clinical significance (pathogenicity class III) in 10 genes associated with channelopathies (KCNQ1, KCNH2, SCN5A, AKAP9, ANK2, SCN10А, RYR2) and cardiomyopathies (MYH7, JPH2, RBM20). Several genetic variants were found in 3 cases. No significant genetic changes were detected in 9 (45 %) probands. The clinical diagnosis was established during the follow-up period and was verified due to the genetic testing in 5 (25 %) patients. From their ECGs, a prolonged QTc 460 ms was found in 1 patient, Brugada pattern in 2 individuals, and a shortening of QTc up to 323 ms in 1 proband. Subclinical structural changes associated with cardiomyopathies were revealed in 2 patients. In 15 (75 %) patients, it was unfeasible to establish a distinct clinical phenotype. In 6 (30 %) probands, the diagnosis was clarified due to detected genetic variants. CONCLUSION: Clinical manifestations and diverse genetic variants have been studied in patients who have survived unexplained cardiac arrest. In the course of genotyping patients who suffered unexplained cardiac arrest, genetic changes associated with LQTS were detected in 30 % of cases, while the QTc in most cases did not exceed 440 ms, which makes it difficult to establish a diagnosis at an early stage before the development of life-threatening arrhythmic events. The data from our study confirm the idea that in patients with idiopathic ventricular fibrillation, who have suffered unexplained cardiac arrest, cardiac channelopathy or subclinical manifestations of cardiomyopathy are commonly the cause. This phenomenon imposes a need for genetic testing in this category of patients.

Impact of the underlying rhythm during cavotricuspid isthmus ablation on the incidence of future new-onset atrial fibrillation: insights from an international multi-centre registry

Abstract Background Radiofrequency catheter ablation of the cavotricuspid isthmus (RF-CTI) is the estabslished treatment of typical atrial flutter (AFL). After RF-CTI for AFL patients without previously documented atrial fibrillation (AF) may also develop AF. It is unknown whether the presence or absence of AFL at the time of ablation can predict the future occurence of AF. Purpose To compare baseline characteristics, procedural data, and long-term follow-up (FU) of patients with AFL. Methods Consecutive patients with documented AFL undergoing RF-CTI were enrolled in a multi-center registry in five centers in two countries between February 2017 and July 2023. For patients with AFL, entrainment mapping was performed for confirming CTI dependent AFL. Patients were categorized into two groups, those with AFL and those with sinus rhythm (SR) during RF-CTI. FU data were collected, including clinical assessments, 12-lead electrocardiogram (ECG) and 24-hour Holter-ECGs during each visit. Results Of the 949 subjects, 36% were excluded from the analysis due to a history of AF. A total of 574 patients were included (mean age 68 +/- 11 yrs, 14% females), 62% presented in AFL group and 38 % SR group during CTI. Median FU was 364 days. Patients in AFL group were older (P &amp;lt; 0.029), more likely to have diabetes (P = 0.026), and were less frequently treated with antiarrhythmic drugs (P &amp;lt; 0.001). In the first 12 months of FU, 40% of the patients underwent three FU examinations, while 77% of the patients underwent at least one 24-hour Holter-ECGs during FU. In the Kaplan-Meier analysis patients in AFL group significantly less often developed AF during FU (log-rank, P &amp;lt; 0.016, central ). In the multivariate Cox regression analysis, sinus rhythm during ablation (hazard ratio 1.474; 95% CI 1.043-2.084; P = 0.028), male gender (hazard ratio 1.722; 95% CI 1.116-2.658; P = 0.014) and coronary artery disease (hazard ratio 1.711; 95% CI 1.145-2.555; P = 0.009) were identified as predictors for the occurence of AF during FU. Conclusion Over a one year follow-up, new onset AF occurs significantly less frequently in patients with ongoing atrial flutter during RF-CTI ablation.

Impact of dapagliflozin on supraventricular and ventricular arrhythmias, assessed by Holter ECG, in patients with heart failure with reduced ejection fraction

Abstract Background &amp; Introduction Dapagliflozin has significantly reduced morbidity &amp; mortality in patients with heart failure with reduced ejection fraction (HFrEF) (1). Some studies reported supraventricular &amp; ventricular arrhythmia suppression, but Holter ECG was underused, hindering precise assessment of arrhythmia burden. Purpose We aim to assess the impact of dapagliflozin on reduction of arrhythmia in HFrEF at 1 year follow-up (FU) by Holter ECG. Methods This is a single center, prospective study. We have screened 219 HFrEF patients, but only 156 patients were enrolled with LVEF &amp;lt;40% in sinus rhythm from December 2021 to July 2023. All patients had dapagliflozin 10 mg once/day tablet with the standard HF therapy. Clinical evaluation, NYHA evaluation, 6-minute walking test (6MWT), echocardiogram, 24-hours Holter ECG and laboratory work-up were done at baseline, and FU at 6 months and 12 months. Results Males constituted 61.5% of study population; mean± SD participants’ age was 56.8 ± 8.6 years. The most common comorbidities were: ischemic etiology (63.3%), dilated cardiomyopathy (28.1%), hypertension (27.3%), smokers (14.7%), and type II diabetes (31.4%). LVEF was ≤ 35% in 85.9% of patients. We have reported (7.69%) deaths during 1-year FU, and 4 patients (2.56%) didn't complete 1-year FU. Main clinical and echocardiographic findings (baseline vs. 1-year FU): NYHA FC III&amp; ambulant IV dropped from (42.9 to 32.9%), P value&amp;lt;0.05. Distance walked in 6MWT improved from 191.52 ± 75.37 to 219.35 ± 71.51 mean± SD meters, P value&amp;lt;0.05. E/e improved (9.4 to 8.3 cm/s, P value &amp;lt;0.01), LVEF improved (31.3 to 36.4%, P value&amp;lt;0.05). HF emergency: [HF visits dropped (23.7 to 19.2%) and HF hospitalization dropped (11.1 to 7.8%)], P value&amp;lt;0.05. Holter ECG (baseline vs. 1-year FU): Supraventricular Arrhythmia: [Paroxysmal AF reduced (56.2 to 47.6%), frequent PACs (≥ 10%) dropped (3.8 to 1.4%) &amp; Intermittent 1st degree heart block dropped (12.5 to 7.3%)] P value &amp;lt;0.01. Ventricular Arrhythmia: [PVCs &amp;gt;5%-&amp;lt;10% dropped (16% to 9.3%), Frequent PVCs &amp;gt;10% dropped (3.2 to 1.4%), and NSVT dropped (7.8 to 3.1%)], P value &amp;lt;0.01. Stepwise logistic regression multivariable model aiming to predict the occurrence of ventricular and supraventricular arrhythmias has indicated a direct linear correlation with male gender, smoking, body mass index, left atrial volume, and a history of myocardial infarction. Conversely, there is an inverse relationship with systolic blood pressure, 6MWT distance, LVEF, and the administration of dapagliflozin (OR 0.72 [0.61 - 1.07], P value &amp;lt;0.01) concerning the likelihood of supraventricular and ventricular arrhythmias. Conclusions Dapagliflozin has demonstrated significant improvement in functional and echocardiographic parameters in HFrEF patients. Furthermore, it has effectively decreased the incidence of supraventricular and ventricular arrhythmias, identified through 24-hour Holter ECG monitoring during 1-year follow-up.

Automatic calculation of the parasympathetic, sympathetic and Baevsky stress indexes provides a more comprehensive assessment of cardiac autonomic modulation

Abstract Background Cardiac autonomic modulation (CAM) is clinically evaluated by measuring the Heart Rate Variability (HRV) parameters, related to sympathetic and parasympathetic efferences to the heart, with linear (L), nonlinear (NL), and time-varying (TV) mathematical methods. Recently, automatic calculation of the parasympathetic (PNSi), sympathetic (SNSi), and Baevsky’s stress (BSTRi) indexes [1,2], integrating some L and NL parameters, has become available for more synthetic assessment of CAM. This study aimed to evaluate in healthy subjects (HS) the normal range of PNSi, SNSi, and BSTRi and their physiological variations during daily activity (ACT) and Non-REM sleep (NREM), taking also into account aging-related changes. Methods 24-hour (H24) Holter ECG recordings of 87 HS, divided into three (Age1, Age2 and Age3) groups (16-34, 35-52, and 53-84 years old, respectively), were retrospectively analyzed with the Kubios software (version 4.0), which automatically calculates the PNSi, SNSi, and BSTRi [1], and time domain (TD), frequency domain (FD), NL and TV HRV parameters. HRV was calculated from H24 and short-term (2 minutes) intervals, selected during ACT and NREM. All HRV calculations were done after "detrending" with the "smooth priors" function (lambda=500). Statistical analysis was performed with SPSS 21. Results Average values of the three indexes and several independent L and NL parameters are summarized in Table 1. Average BSTRi values of each age group were not different between ACT and NREM, whereas significant (p&amp;lt;0.05) increments between Age3 and Age1 (during ACT) and between Age3 and both Age1 and 2 (during NREM and H24) were found. Average SNSi values were slightly above the normality range [1] during ACT, or normal (during NREM and H24). Average PNSi values were within the suggested normality range [1] with minimal aging-related variations. Significant aging-related decrement of the selected TD and FD parameters was found in all analysed conditions. Among NL parameters, the correlation dimension (D2) values showed significant aging-related decrement (H24 and NREM), while H24 and ACT sample entropy (SampEn) was lower in Age1 and Age2, compared with Age3 (p&amp;lt;0.05). An example (H24 analysis of Age3 data) of significant (p&amp;lt;0.01) correlation among the three indexes and the selected independent linear and non-linear parameters is shown in Figure 1. Conclusions In this study, a significant aging-related increment of BSTRi was found in all investigated conditions. PNSi and SNSi were always within the suggested normality range [1]. In spite of the significant changes of linear parameters consistent with the well-known aging-related decrement of HRV, the higher SampEn (and BSTRi) found in Age3 HS suggests that an "healthy elderly", is characterized by a more complex adaptation of CAM, likely mediated also by the observed moderate (healthy?) increment of physiological stress. However further investigation on a broader population is warranted.Table 1Figure 1

Effects of baroreceptor reflex modification on efficacy of ablation for atrial fibrillation

Abstract Background The autonomic nervous system (ANS) plays a significant role in atrial fibrillation (AF). Catheter ablation (CA) is a well-established treatment method for AF and significantly affects ANS, including baroreceptors (BR) function. However, little is known about the changes in the BR function caused by radiofrequency (RF) or cryo-energy (CB) influence the efficacy of AF ablation. Purpose To assess one-year efficacy of CA of AF in relation to BR function modification and type of ablation energy used. Methods The study group consisted of 78 patients (25 females, mean age 58±9 years) with paroxysmal AF and first CA (39 patients (RF group) and 39 (CB group)). The BR function was assessed non-invasively using tilt testing and three parameters: event count (BREC) depicting overall BR activity, slope mean depicting BR sensitivity (BRS) and BR effectiveness index (BEI). The efficacy of CA was assessed at 3, 6, and 12 months after CA using 24-hour Holter ECG recordings and dedicated scale (University of Toronto Atrial Fibrillation Severity Scale (AFSS)). Results After CA, BR function decreased in the whole group (mean BREC 12.0±3.0-22.0 vs 6.0±3.0-18.0, p=0.004; mean BRS 4.8±3.6-6.8 vs 4.0±3.0-5.8, p=0.014; mean BEI 18.7±8.3-27.4 vs 12.0±5.1-21.0, p=0.009). BREC was significantly more decreased in the CB vs RF (mean 12.0±3.0-22.0 vs 6.0±3.0-18.0, p=0.004). Similar trend was noted for BRS and BEI. On repeated Holter ECG monitorings efficacy of CB and RF was similar (89.7% vs 82.9% p=0.502, 89.7 vs 85.7%; p=0.727 and 84.6 vs 80%; p=0.602, respectively). According to AFSS, the AF symptoms were significantly reduced in both groups (CB baseline vs 3, 6 a and 12 months, respectively (median): 6.0 (IQR 2.0 – 13.0) vs 2.5 (IQR 1.0 – 4.0), p&amp;lt;0.001; 6.0 (IQR 2.0 – 13.0) vs 1.5 (IQR 0.0 – 4.0), p&amp;lt;0.001; 6.0 (IQR 2.0 – 13.0) vs 1.5 (IQR 0.0 – 4.0), p=0.002; RF baseline vs 3, 6 and 12 months, respectively (median): 10.5 (IQR 5.0 – 14.0) vs 7.0 (IQR 1.0 – 12.0), p=0.173; 10.5 (IQR 5.0 – 14.0) vs: 6.0 (IQR 2.0 – 12.0), p=0.015; 10.5 (IQR 5.0 – 14.0) vs 6.5 (IQR 2.0 – 12.0), p=0.005). After the adjustment for baseline there was no significant differencies between both groups (Table). Conclusions CA significantly affected BR function. These changes were more pronounced following CB than RF CA. However, the efficacy of RF and CB was similar.

Ventricular and supraventricular ectopic beats burden is correlated with bone mineral density and osteoporotic fracture risk in postmenopausal females

Abstract Introduction Patients (pts) with osteoporosis (OP) have an increased 10-year cardiovascular death risk. Low bone mineral density (BMD) observed in OP may be associated with arrhythmic presentation of cardiovascular diseases (CVD). Few studies assessed the relationship between OP and arrhythmia. Aim Arrhythmias assessment in pts with OP. Methods A total of 103 postmenopausal female pts (mean age 69 +/- 7), consulted by endocrinologist, were divided into 2 groups according to BMD (assessed by dual energy X-ray absorptiometry). BMD measurements, expressed as T-score (T-sc), were taken from the femoral neck (T-sc Neck), entire total hip (T-sc TH) and/or spine (T-sc L2-L4, L1-L4). Arrhythmia was evaluated using 24-hour Holter-ECG monitoring (HM). Major osteoporotic and total hip fracture risks (MOFR and THFR, respectively) were assessed by the FRAX scale. We compared 51 pts with OP (T-sc ≤ -2.5), with 52 matched controls without OP, including 44 pts with osteopenia (T-sc &amp;gt; -2.5). There were no significant differences between the groups regarding the history of stroke, myocardial infarction, coronary artery disease or arterial hypertension. Exclusion criteria included heart failure NYHA &amp;gt;II and/or LVEF &amp;lt;36%, acute coronary syndrome within the last 6 months, severe valvular disease, cardiac implantable electronic device. Results There was a trend towards a greater number of supraventricular and ventricular arrhythmias in the OP group compared to the controls. Arrhythmic burden was significantly correlated with BMD measures: correlations were observed between 24-hour ventricular ectopic beats (VEB) count with T-sc Neck (r=-0.20, p=0.04), with T-sc TH (r=-0.22, p=0.03). The number of supraventricular ectopic beats (SVEB) in HM was also correlated with BMD parameters: T-sc Neck (r=-0.21, p=0.03), T-sc TH (r=-0.23, p=0.02). Multivariate analysis (linear regression model) revealed that age and T-sc TH were independently related with ectopy: age (0.07; CI: 0.01 - 0.13, p=0.03) and T-sc TH (-0.58; CI: -1.07 - -0.08, p=0.02) were predictors for VEB, and SVEB were related to age (0.07; CI: 0.03 - 0.12, p&amp;lt;0.01) and, with borderline significance with T-sc TH (-0.34; CI: -0.699 - 0.012, p=0.058). Ectopic beats count was also positively correlated with osteoporotic fracture risk: VEB with THFR (r=0.206, p=0.04) and SVEB with MOFR (r=0.21, p=0.04). Conclusions The study showed an increased arrhythmia burden as detected in HM in pts with OP. Beside the T-sc TH, age was identified as an independent factor of increased SVEB / VEB. The main significant negative correlations were observed between the number of VEB / SVEB and BMD in femur (T-sc Neck, T-sc TH). Ectopic beats count was also positively correlated with osteoporotic fracture risk: VEB with THFR and SVEB with MOFR.

Ventricular arrhythmias occurring in myocardial infarction patients with acute ST-segment elevation within the first 24 hours after primary percutaneous coronary intervention and their prognostic value

Reperfusion therapy in myocardial infarction patients with acute ST-segment elevation significantly reduced the frequency of ventricular tachycardia and ventricular fibrillation, however, such arrhythmias still occur in 6-8% of patients, posing a threat to their lives.The aim of the study was to determine the nature of ventricular arrhythmias occurring in myocardial infarction patients with acute ST-segment elevation within the first 24 hours after primary percutaneous coronary intervention, and their prognostic value regarding the development of complications during the inpatient treatment phase. The study involved 82 individuals (mean age: 62,4±10,2 years; male: 69,23 (58,6-78,92)%, female: 30,77 (21,08-41,4)%). Within 24 hours after the infarct-related artery stenting, all patients underwent a 24-hour Holter ECG monitoring. The course of the disease was analyzed based on the presence of risk factors such as hypertension, diabetes mellitus, past COVID-19, and obesity. Ventricular rhythm disturbances were represented mainly by premature contractions. They occurred significantly more frequently in patients with arterial hypertension (883,71 (96,0; 986.0); p=0,02; p=0,03; p=0,02, compared to patients with a history of COVID-19, diabetes, and obesity, respectively) and in those with past COVID-19 (711,3 (125,0; 846,5); p=0,01; p=0,04, compared to indi­viduals with diabetes and obesity, respectively). Isolated premature ventricular complexes, pairs, triplets were recorded, and in individuals with arterial hypertension and past COVID-19 “runs” of ventricular extrasystoles and episodes of nonsustained monomorphic and even polymorphic ventricular tachycardia, such as Torsades de Pointes, (under the condition of combined risk factors) were noted; predominantly in these patients during the hospital phase such сom­plications as ventricular fibrillation and asystole,with sudden cardiac arrest developed. The obtained results is an evidence of electrical myocardial instability and indicate that myocardial infarction patients with acute ST-segment elevation, in addition to myocardial revascularization, require optimization of pharmacological treatment. The use of intravenous beta-blockers as part of complex treatment prevented the occurrence of life-threatening ventricular arrhythmias during the inpatient treatment phase.

Prevalence and Associated Factors of Paroxysmal Atrial Fibrillation and Atrial Arrhythmias During Hospitalizations for Exacerbation of COPD.

This study aimed to investigate the proportion and risk factors of paroxysmal atrial fibrillation (AF) and atrial arrhythmias (AA) in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in Vietnam. A prospective observational study was conducted at two major hospitals in Hanoi, Vietnam, from January 2022 to January 2023. A total of 197 AECOPD patients were recruited. ECG and 24-hour Holter ECG were used to diagnose paroxysmal AF and AA. The prevalence of paroxysmal AF and AA were 15.2% and 72.6%, respectively. Factors associated with a higher likelihood of paroxysmal AF included aging 75 years old and above (aOR = 3.15; 95% CI: 1.28 to 8.48), Premature atrial complex (PAC) with 500 or more (aOR = 3.81; 95% CI: 1.48 to 10.97) and severity of COPD as group C and D (aOR = 3.41; 95% CI: 1.28 to 10.50). For AA, aging 75 years old and above (aOR = 2.25; 95% CI: 1.28 to 5.20), smoking (aOR = 2.10; 95% CI: 1.07 to 4.23) and P wave dispersion (PWD) with 40 milliseconds or more (aOR = 3.04; 95% CI: 1.54 to 6.19) were associated with a higher likelihood of AA. Overall, our findings highlight the associated factors with the paroxysmal AF and AA among AECOPD patients. This underscores the importance of a multifaceted approach to risk assessment and management in this vulnerable population, focusing not only on respiratory symptoms but also on comprehensive cardiovascular evaluation and intervention.

Advanced Atrioventricular Block in Athletes: Prevalence and Role of Anti-Ro/Sjögren Syndrome-Related Antigen A Antibodies.

Advanced atrioventricular block (AVB), that is, higher than second-degree Mobitz-1, is an abnormal finding in athletes. Despite intensive investigation, in several cases the pathogenesis remains unknown, but frequently pacemaker implantation is still indicated. Increasing evidence points to circulating anti-Ro/Sjögren syndrome-related antigen A (SSA) antibodies cross-reacting with L-type calcium channel and inhibiting the related current as an epidemiologically relevant and potentially reversible cause of isolated AVB in adults. The aim of the study was to determine the prevalence of anti-Ro/SSA-associated advanced AVBs in a large sample of young athletes. A total of 2536 consecutive athletes aged <40 years without a history of cardiac diseases/interventions were enrolled in a cross-sectional study. Resting and exercise electrocardiography was performed, and those presenting any AVB were further evaluated by 24-hour Holter ECG. Athletes with second-degree AVBs and their mothers underwent anti-Ro/SSA testing. Moreover, purified immunoglobulin G from subjects with anti-Ro/SSA-positive and anti-Ro/SSA-negative advanced AVB were tested on L-type calcium current and L-type-calcium channel expression using tSA201 cells. The global prevalence of advanced AVB in the overall sample was ≈0.1%, but the risk considerably increased (2%) when intensely trained postpubertal male subjects were selectively considered. While none of the athletes with advanced AVB showed heart abnormalities, in 100% of cases anti-Ro/SSA antibodies were detected. Exvivo experiments showed that immunoglobulin G from anti-Ro/SSA-positive but not -negative subjects with advanced AVB acutely inhibit L-type calcium current and chronically downregulate L-type-calcium channel expression. Our study provides evidence that advanced AVB occurs in young athletes, in most cases associated with anti-Ro/SSA antibodies blocking L-type calcium channels. These findings may open new avenues for immunomodulating therapies to reduce the risk of life-threatening events in athletes, avoiding or delaying pacemaker implantation.

Мікроциркуляція та варіабельність серцевого ритму при хронічній ішемічній хворобі серця і COVID-19

COVID-19 is associated with a wide range of negative effects on the cardiovascular system. The aim of our study was to investigate the impact of COVID-19 on the interdependence of changes in the microcirculation system and heart rate variability in patients with chronic coronary artery disease (CAD). An ECG study was performed in 12-lead leads, as well as 24-hour Holter ECG monitoring and laser Doppler flowmetry (LDF). Patients were divided into 3 groups. Group 1 included patients with coronary artery disease (n = 32), group 2 - with coronary artery disease in combination with COVID-19 (n = 35), and group 3 - with COVID-19 (n = 35). The control group consisted of 30 conditionally healthy individuals. All subjects were determined: microcirculation index, capillary blood flow reserve of the occlusion test, as well as nitroglycerin test and wavelet transform indicators (the relationship between the frequency and amplitude of microcirculatory oscillations, which are divided into endothelial, neurogenic, myogenic, respiratory and cardiac mechanisms of microcirculation regulation). The deterioration of endothelial function, as measured by the maximum amplitude of endothelial flux motions, should be noted, and a decrease in the endotheliumdependent and endothelium-independent components of microcirculation regulation. The capillary blood flow reserve of the occlusion test in patients with CAD in combination with COVID-19 was lower than in patients with CAD (group 1) and COVID-19 (group 3). In patients of the study groups, the total heart rate variability decreased, parasympathetic activity was weakened, and the QT interval duration and its variability increased compared with controls. These changes were most pronounced in patients with coronary artery disease in combination with COVID-19 in terms of the standard deviation of all intervals, the parasympathetic component of regulation, and both characteristics of the QT interval. Thus, patients with chronic CAD and concomitant COVID-19, along with endothelial dysfunction and worsening venous outflow, showed signs of autonomic dysregulation and increased QT interval duration and variability. Additional consideration of the characteristics of the microcirculatory bed, heart rate variability and QT interval is advisable in the examination system of such patients.

Neutrophil-to-Lymphocyte Ratio as a Marker for Cardiac Autonomic Neuropathy in Egyptian Patients With Type 2 Diabetes: A Cross-Sectional Study.

Cardiac autonomic neuropathy (CAN) is one of the most serious complications of diabetes. This study aimed to analyze the correlation between neutrophil-to-lymphocyte ratio (NLR) and CAN in patients with type 2 diabetes (T2D) using 24-hour Holter ECGand to assess the relationship between NLR and severity of diabetic peripheral neuropathy (DPN). Thiscross-sectional studyincluded 90 T2D patients with DPN confirmed by nerve conduction study (NCS). A 24-hour Holter ECG was done to detect the decrease in heart rate variability (HRV). Laboratory parameters, including fasting blood glucose, creatinine, cholesterol, triglyceride, and glycosylated hemoglobin (HbA1c) levels, as well as CBC, neutrophils, lymphocytes, NLR, and platelet-to-lymphocyte ratio (PLR), were calculated accordingly. An albumin-to-creatinine ratio (ACR) test was done and the estimated glomerular filtration rate (eGFR) was calculated. Chronic kidney disease was diagnosed by the presence of albuminuria (≥30 mg/g creatinine) and/or eGFR less than 60. Based on the 24-hourHolter ECG, 25 patients out of 90 (27.7%) had CAN. On comparing both the CAN and non-CAN groups, the CAN group had higher HbA1C (p = 0.005), higher NLR (p = 0.014), and higher neutrophils (p = 0.10). Also, PLR was higher in the CAN group than in the non-CAN group, but this was not statistically significant (p = 0.180). Receiver operator characteristic curve analysis revealed that NLR with a cutoff of 1.7 succeeded in detecting patients with CAN. NLR can be used as an inexpensive and accessible marker to detect patients with diabetes at risk for developing CAN.

Clinical and Therapeutic Aspects of Ischemic Stroke in Atrial Fibrillation at the Neurology Department of CHU Conakry

Introduction: The main cause of ischemic stroke in our setting is atrial fibrillation. The aim of this study was to evaluate the clinical and therapeutic aspects of atrial fibrillation during ischemic stroke. Material and Methods: We conducted a retrospective descriptive study lasting one year from November 1, 2020 to November 31, 2021, involving all patients with ischemic stroke diagnosed by CT or MRI. We included patients with atrial fibrillation confirmed by a 12-lead électrocardiogrammes (ECG) or a 24-hour ECG holter. Thromboembolic risk was assessed by the CHA2DS2Vasc score and bleeding risk by the HAS-BLED score. Results: A total of 1,400 patients (19.64%) were enrolled. Mean age was 57.3 +/-16.64 years, predominantly female (54.5%), with hypertension as a risk factor (45.09%). The mean NIHSS score was 17.9 +/-3.2, associated with disorders of consciousness (44.36%) and hemiplegia (100%). atrial fibrillation was persistent in 54.90% of cases. A CHA2DS2-VASc score ≥ 2 was found in 94.9% of cases, and a low HAS-BLED score in 73% of cases, for whom Rivaroxaban was the first-line treatment in 76.72% of cases. Conclusion: This study has shown that atrial fibrillation is common in cardioembolic cerebral infarctions with age and hypertension as risk factors.

Heartbeat Chronicles: Decoding the Interplay of Echocardiography and Heart Rate Variability in Chronic Heart Failure Patients – Unraveling the Mysteries with Traditional and Advanced 24-Hour Holter ECG Parameters

Abstract Objective Chronic heart failure (CHF) is a clinical syndrome that encompasses individuals who either have received a definitive diagnosis of heart failure or display a gradual escalation of symptoms as time elapses. Echocardiography, particularly evaluating left ventricular function, is crucial for diagnosis and prognosis. However, 24-hour Holter monitoring, focusing on heart rate variability (HRV), provides insights into autonomic dynamics and vulnerability. Recent HRV parameters offer nuanced information, enhancing risk stratification and guiding personalized interventions in CHF. The interplay between echocardiography and HRV enables a comprehensive approach, refining the management of CHF by considering both cardiac structure and autonomic regulation. Methods This prospective study at “St. Spiridon” County Hospital involved 80 patients with left ventricular ejection fraction (LVEF) &lt; 50%. The diagnosis was according to standard clinical echocardiography, laboratory panel, and Holter ECG monitoring. Results Unexpectedly, no statistically significant relationship was found between commonly used HRV parameters and echocardiographic parameters. Further analyses showed statistically significant associations between non-traditional HRV parameters and E/A ratio, E/E’, and S’ lateral and septal. Additionally, modifications in HRV parameters were correlated with mitral valve deceleration time, left atrial volume index, estimated pulmonary artery systolic pressure, and cardiac output. Conclusions Less commonly used Holter ECG parameters, such as acceleration capacity, deceleration capacity, and triangular index, demonstrated significant diagnostic efficacy, especially when conventional HRV parameters were normal. This highlights the importance of incorporating non-traditional HRV parameters in CHF patient risk stratification, urging further exploration through comprehensive multicenter studies for long-term prognostic implications.

Heart rate dynamics after pulmonary vein isolation: pulsed-field vs. radiofrequency ablation

Abstract Background The autonomic nervous system (ANS) plays a pivotal role in the onset and maintenance of atrial fibrillation (AF). During thermal ablation, the epicardial ganglionated plexi (GP) can inadvertently be affected, as indicated by a post-ablation increase in heart rate (HR), potentially impacting post-procedural outcomes. Pulsed-field ablation (PFA) offers a safer and potentially more effective alternative, as lesion transmurality is not inversely related to safety as in thermal ablation. However, PFA's tissue selectivity may limit its effectiveness in ablating potential AF triggers like GP. Purpose We aimed to assess the impact of PF and RF energy on GP ablation by examining HR changes following PVI procedures. Methods We examined consecutive paroxysmal AF patients undergoing PVI at a single center, using either a variable-loop circular PFA catheter, as part of the inspIRE trial, or a conventional point-by-point RF catheter (1:2 ratio). ECGs were collected before and after ablation at multiple time points, including 1-hour, 1-day, 1-month, and 3-month intervals, with a 24-hour Holter ECG at 3 months. Patients without obtainable sinus rhythm ECGs at these time points were excluded. We also gathered data on post-ablation antiarrhythmic drug and beta-blocker usage. Data are reported as mean±SD, and analysis employed Student’s t-tests, paired t-tests, chi-squared tests, and multiple linear regression analysis to identify influencing factors. Results A total of 105 patients were included (PF = 35, RF = 70). Baseline demographics were similar (Table A). In the RF group, HR significantly increased at all measured time-points. In contrast, this trend was not observed in the PF group (Figure A and B). Following the procedure, the RF cohort exhibited a significantly higher HR compared to PF (7.3±10.3 vs. 0.8±11 at 1-day, p=0.018), and this difference persisted after 3 months (8.5±10.1 vs. 0.9±9, p&amp;lt;0.001, Figure C). These findings remained consistent when HR was assessed using Holter ECG data (HR at 3 months: mean 72.1±8.8 vs 65.8±9.4, min 55.2 vs 48.9; p=0.002, p=0.001, Figure D). The use of RF energy was the only predictor of HR increase after the ablation procedure (β = 7.687, p &amp;lt; 0.001, Table B). Conclusion Our findings indicates that PFA does not increase resting HR as seen with thermal RF ablation, suggesting limited effect on ANS modulation. The role of adjunctive GP ablation during PVI procedures remains a topic of debate.While PFA shows promising improvement in lesion durability, current evidence does not conclusively establish its advantage over RF. This invites contemplation about whether the addition of GP ablation in RF procedures could be a contributing factor. The absence of HR acceleration may pose issues for patients with sick sinus syndrome or pure vagally mediated AF. Further research is essential to confirm these findings and their clinical implications.Central illustrationTables

THE IMPORTANCE OF CARDIAC MAGNETIC RESONANCE IMAGING IN THE ASSESSMENT OF THE RISK OF CARDIAC ARRHYTHMIAS IN PATIENTS WITH ARTERIAL HYPERTENSION

Objective: Arterial hypertension leads to organ changes, including left ventricular hypertrophy. The increased mass of left ventricle increases the risk of cardiac arrhythmias, which enhances the risk of sudden cardiac death. Cardiac magnetic resonance imaging (CMRI) can identify the presence of myocardial fibrosis by assessing late gadolinium enhancement (LGE). The aim of the study was to assess the relationship between the presence of late gadolinium enhancement at the right ventricular insertion point (RVIP) determined by CMRI and the occurrence of cardiac arrhythmias in patients with arterial hypertension. Design and method: 30 patients with essential hypertension were qualified for the study, 18 men and 12 women, the average age of the subjects was 55.5 ± 12.4 years. All subjects underwent cardiac magnetic resonance imaging and 24-hour Holter ECG monitoring. Based on the presence of LGE at the right ventricular insertion point, assessed by CMRI, the subjects were divided into two subgroups. The first subgroup consisted of subjects with LGE at the right ventricular insertion point (RVIP + subgroup), while the second subgroup consisted of subjects without LGE at the right ventricular insertion point (RVIP - subgroup). Results: Subjects with LGE at the right ventricular insertion point were characterized by higher maximum and minimum heart rates in 24-hour Holter ECG recordings compared to subjects without LGE at the right ventricular insertion point (p &lt; 0.05). In subjects with LGE at the right ventricular insertion point, Holter ECG evaluation revealed a statistically significantly higher number of single premature supraventricular beats, single premature ventricular beats and supraventricular tachycardias compared to subjects without LGE at the right ventricular insertion point (p &lt; 0.05). The regression analysis performed showed that a longer time from the diagnosis of hypertension and the occurrence of LGE at the right ventricular insertion point assessed using CMRI are independent risk factors for cardiac arrhythmias (p &lt; 0.05). Conclusions: Cardiac magnetic resonance imaging by identifying of late gadolinium enhancement at the right ventricular insertion point may be a useful diagnostic method in assessing the risk of cardiac arrhythmias in a group of patients with arterial hypertension.

Higher Frequency of Premature Atrial Contractions Correlates With Atrial Fibrillation Detection after Cryptogenic Stroke.

Covert atrial fibrillation (AF) is a major cause of cryptogenic stroke. This study investigated whether a dose-dependent relationship exists between the frequency of premature atrial contractions (PACs) and AF detection in patients with cryptogenic stroke using an insertable cardiac monitor (ICM). We enrolled consecutive patients with cryptogenic stroke who underwent ICM implantation between October 2016 and September 2020 at 8 stroke centers in Japan. Patients were divided into 3 groups according to the PAC count on 24-hour Holter ECG: ≤200 (group L), >200 to ≤500 (group M), and >500 (group H). We defined a high AF burden as above the median of the cumulative duration of AF episodes during the entire monitoring period. We evaluated the association of the frequency of PACs with AF detection using log-rank trend test and Cox proportional hazard model and with high AF burden using logistic regression model, adjusting for age, sex, CHADS2 score. Of 417 patients, we analyzed 381 patients with Holter ECG and ICM data. The median age was 70 (interquartile range, 59.5-76.5), 246 patients (65%) were males, and the median duration of ICM recording was 605 days (interquartile range, 397-827 days). The rate of new AF detected by ICM was higher in groups with more frequent PAC (15.5%/y in group L [n=277] versus 44.0%/y in group M [n=42] versus 71.4%/y in group H [n=62]; log-rank trend P<0.01). Compared with group L, the adjusted hazard ratios for AF detection in groups M and H were 2.11 (95% CI, 1.24-3.58) and 3.23 (95% CI, 2.07-5.04), respectively, and the adjusted odds ratio for high AF burden in groups M and H were 2.57 (95% CI, 1.14-5.74) and 4.25 (2.14-8.47), respectively. The frequency of PACs was dose-dependently associated with AF detection in patients with cryptogenic stroke.